• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Kimberly Stegmaier, MD


  • Crompton BD, Carlton AL, Thorner AR, Christie AL, Du J, Calicchio ML, Rivera MN, Fleming MD, Kohl NE, Kung AL, Stegmaier K.High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma.Cancer Res. 2013 Apr 22.
  • Roti G, Carlton A, Ross KN, Markstein M, Pajcini K, Su AH, Perrimon N, Pear WS, Kung AL, Blacklow SC, Aster JC, Stegmaier K.Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer.Cancer Cell. 2013 Mar 18;23(3):390-405.
  • Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, McDermott U, Benes CH, Kung AL, Weiss WA, Bradner JE, Stegmaier K.Targeting MYCN in neuroblastoma by BET bromodomain inhibition.Cancer Discovery. 2013 Mar;3(3):308-23.
  • Stegmaier K.Chemical genomics and combo therapy.Blood. 2010 Dec 23;116(26):5786-8.
  • Aste-Am├ęzaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M, Huang L, Vitelli S, Vo KT, Haytko P, Zhao JZ, Baleydier F, L'Heureux S, Wang H, Gordon WR, Thoryk E, Andrawes MB, Tiyanont K, Stegmaier K, Roti G, Ross KN, Franlin LL, Wang H, Wang F, Chastain M, Bett AJ, Audoly LP, Aster JC, Blacklow SC, Huber HE.Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.PLoS ONE. 2010;5(2):e9094.
  • Hahn CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K, Schinzel AC, Ross L, Galinsky I, Davis TN, Silver SJ, Root DE, Stone RM, DeAngelo DJ, Carroll M, Hahn WC, Carr SA, Golub TR, Kung AL, Stegmaier K.Proteomic and genetic approaches identify Syk as an AML target.Cancer Cell. 2009 Oct 6;16(4):281-94.
  • Corsello SM,Roti G,Ross KN,Chow KT,Galinsky I,Deangelo DJ,Stone RM,Kung AL,Golub TR,Stegmaier K.Identification of AML1-ETO modulators by chemical genomics.Blood. 2009 Jun 11;113(24):6193-205.
  • DuBois SG,Krailo MD,Lessnick SL,Smith R,Chen Z,Marina N,Grier HE,Stegmaier K.Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group.Pediatr Blood Cancer. 2009 Mar;52(3):324-7.
  • Haining WN,Angelosanto J,Brosnahan K,Ross K,Hahn C,Russell K,Drury L,Norton S,Nadler L,Stegmaier K.High-throughput gene expression profiling of memory differentiation in primary human T cells.BMC Immunol. 2008;9:44.
  • Hahn CK,Ross KN,Warrington IM,Mazitschek R,Kanegai CM,Wright RD,Kung AL,Golub TR,Stegmaier K.Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9751-6.
  • Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J, Hahn WC, Chiosis G, Golub TR.Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.Cancer Cell. 2006 Oct;10(4):321-30.
  • Peck D, Crawford ED, Ross KN, Stegmaier K, Golub TR, Lamb J.A Method for High-Throughput Gene Expression Signature Analysis.Genome Biol. 2006 Jul 19;7(7):R61.
  • Stegmaier K.Genomic approaches in acute leukemia.Best Pract Res Clin Haematol. 2006;19(2):263-8. Review.
  • Xu K, Guidez F, Glasow A, Chung D, Petrie K, Stegmaier K, Wang KK, Zhang J, Jing Y, Zelent A, Waxman S.Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated .Cancer Res. 2005 Sep 1;65(17):7856-65.
  • Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR.Gefitinib induces myeloid differentiation of acute myeloid leukemia.Blood. 2005 Oct 15;106(8):2841-8.
  • Stegmaier K, Ross KN, Colavito SA, O'Malley S, Stockwell BR, Golub TR.Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation.Nat Genet. 2004 Mar;36(3):257-63.
  • Golub TR, Barker GF, Stegmaier K, Gilliland DG.The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms.Curr Top Microbiol Immunol. 1997;220:67-79.
  • McLean TW, Ringold S, Neuberg D, Stegmaier K, Tantravahi R, Ritz J, Koeffler HP, Takeuchi S, Janssen JW, Seriu T, Bartram CR, Sallan SE, Gilliland DG, Golub TR.TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia.Blood. 1996 Dec 1;88(11):4252-8.
  • Golub TR, McLean T, Stegmaier K, Carroll M, Tomasson M, Gilliland DG.The TEL gene and human leukemia.Biochim Biophys Acta. 1996 Aug 8;1288(1):M7-10.
  • Stegmaier K, Takeuchi S, Golub TR, Bohlander SK, Bartram CR, Koeffler HP.Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia.Cancer Res. 1996 Mar 15;56(6):1413-7.
  • Golub TR, Barker GF, Stegmaier K, Gilliland DG.Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms.Curr Top Microbiol Immunol. 1996;211:279-88.
  • Stegmaier K, Pendse S, Barker GF, Bray-Ward P, Ward DC, Montgomery KT, Krauter KS, Reynolds C, Sklar J, Donnelly M.Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood.Blood. 1995 Jul 1;86(1):38-44.